(redirected from Receptor tyrosine kinases)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: receiver
Mentioned in ?
References in periodicals archive ?
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases.
Recent guidelines from International Association for the Study of Lung Cancer/Association for Molecular Pathology/College of American Pathologists recommend at minimum EGFR and anaplastic lymphoma receptor tyrosine kinase (ALK) testing on all tumors with adenocarcinoma histology (including adenosquamous, adeno--small cell neuroendocrine, and poorly differentiated) (1).
The Wnt receptor CRD domain is also found in MuSK and related orphan receptor tyrosine kinases.
A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers -- combine them with inhibitors of the MEK/ERK signaling pathway.
The evidence is reviewed that suggests that K-dependent proteins are ligands for receptor tyrosine kinases, which, in the rapidly proliferating cell milieu of the fetus, control growth regulation.
Consistent with the effect of ENMD-2076 free base on several receptor tyrosine kinases, inhibition of phosphorylation of proteins in the oncogenic PI3-kinase/Akt pathway including p-BAD, p-FOXO1a, and p-GSK3beta was observed.
Eph receptor tyrosine kinases and their ligands, the ephrins, are involved in a variety of biological processes, including normal embryonic development, cell adhesion, cell migration, tissue morphogenesis, angiogenesis and cancer.
Receptor tyrosine kinases have been widely implicated in the generation and progression of common human tumors, including HNSCC.
She will be a key part of our strategy to actively pursue collaborations and other alliances to further expand and develop our first-in-class product pipeline based on the biology of receptor tyrosine kinases," commented Dr.
The RAS/RAF/MEK/ERK (MAP Kinase) signaling pathway is frequently hyperactivated in a wide range of cancers through mutations in upstream targets such as BRAF, RAS and receptor tyrosine kinases.
Kolltan Pharmaceuticals is a privately held company focused on the discovery and development of novel, antibody-based drugs targeting receptor tyrosine kinases (RTKs).

Full browser ?